Work

Biomarkers associated with response to neoadjuvant chemoimmunotherapy in non-small cell lung cancer

Year: 2025

Type: article

Abstract: Epidemiological studies show that non-small cell lung cancer (NSCLC) is the most common variant of lung cancer and is the main source of disease in many populations. Neoadjuvant chemoimmunotherapy (NCIO) is a frequent treatment for NSCLC and has been shown to increase median event-free survival and pathological complete response (pCR) rates. However, many patients do not respond to this treatment and still experience disease progression. To help clinicians plan personalized treatments, it is crucial to identify biomarkers that can predict the effectiveness of NCIO. pCR could help as an intermediate marker for predicting event-free survival in neoadjuvant therapy trials. In this review, we summarize the biomarkers studied through imaging, clinical data analysis, tumor microenvironment studies, and gene expression profiling. These biomarkers support personalized medicine and better survival for cancer patients.

Source: ONCOLOGIE

DOI: 10.1515/oncologie-2025-0346

Authors: Hao Wu, Honglin Yan, Yang Cheng, Jingping Yuan, Honglei Chen

Institutions: Wuhan University, Renmin Hospital of Wuhan University, General Hospital of Central Theater Command, Zhongnan Hospital of Wuhan University

Language: English

Topic: Lung Cancer Diagnosis and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $1,130